PCR results showed that treatment with the TBFS-containing serum significantly increased the HDAC2 expression level in the COPD cell model; WB results showed that serum TBFS significantly increased the expression of GR-α and HDAC2 and decreased the expression of P-AKT1. This evidence concerns the gene HDAC2 and chronic obstructive pulmonary disease.